PHARMAC
TE PĀTAKA WHAIORANGA

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cancer Treatments Advisory Committee Provisional recommendations 9 October 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.
More information about provisional recommendations is on Pharmac's website

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Polatuzumab vedotin for people with diffuse large B-cell lymphoma (International Prognostic Index = 2-5), within the context of treatments of malignancy and subject to Special Authority criteria	Low Priority
Polatuzumab vedotin for people with diffuse large B-cell lymphoma (International Prognostic Index = 3-5), within the context of treatments of malignancy and subject to Special Authority criteria	Medium Priority
Glofitamab (with chemotherapy) for people with relapsed or refractory diffuse large B-cell lymphoma in the ≥ second line setting, within the context of treatment of malignancy, subject to Special Authority criteria	High Priority
Epcoritamab for people with relapsed or refractory diffuse large B-cell lymphoma in the ≥ third line setting, within the context of treatment of malignancy, subject to Special Authority criteria	High Priority
Momelotinib for the first-line treatment of intermediate or high-risk primary myelofibrosis (MF), post-polycythaemia vera MF or post-essential thrombocythaemia MF, with moderate to severe anaemia, within the context of treatment of malignancy, subject to Special Authority criteria	Cost Neutral* to ruxolitinib
Momelotinib for the second-line treatment of intermediate or high-risk primary myelofibrosis (MF), post-polycythaemia vera MF or post-essential thrombocythaemia MF, with moderate to severe anaemia, within the context of treatment of malignancy, subject to Special Authority criteria	High Priority

*Cost Neutral – The Committee has recommended this application be funded if the cost is neutral to the provision of the currently funded medicine including health system costs

**Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website.

Released 21 November 2025

A1957654